Compare Estee Lauder Companies Inc (EL) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Estee Lauder Companies Inc vs Novavax Inc — how do they compare? Estee Lauder Companies Inc trades at $82.64 (market cap $29.78B), while Novavax Inc trades at $8.3 (market cap $1.39B). The key difference: Estee Lauder Companies Inc is far larger — about 21.4× Novavax Inc's market cap, and Estee Lauder Companies Inc pays a 1.7% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| EL | NVAX | |
|---|---|---|
Market Cap | $29.78B | $1.39B |
Sector | Consumer Staples | Health |
52-Week High | $119.61 | $11.19 |
52-Week Low | $67.23 | $6.22 |
Enterprise Value | $35.95B | $890.94M |
Dividend Yield | 1.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Estée Lauder (EL) trades at $80.86, down 0.36% on the day, with a bearish technical signal and recent earnings beats. The stock shows a high P/E of 147.8 and negative net income margin of -1.67%, though revenue remains substantial at $14.33 billion for 2025. Recent news highlights innovation in beauty trends, but cash flow trends show net outflows over recent years.
Outlook is mixed: analyst consensus targets $90.60 with 44% buy ratings, but high valuation and profitability challenges pose risks. Recovery depends on margin improvement and sustained revenue growth amid competitive pressures.
Novavax (NVAX) trades at $8.42, down 5.5% on the day, reflecting a bearish technical trend. Despite a low P/E of 3.14 and recent earnings beats, the company reported a net loss margin of -14.73% for 2026 and negative cash flows. Analyst consensus is a 'Buy' with a $14.00 price target, but technical indicators signal selling pressure. Recent news highlights stock volatility and shareholder dissent at the AGM.
The outlook is mixed: strong valuation ratios and earnings beats offer upside potential, but persistent negative cash flow, high debt, and competitive pressures pose significant risks. Investor sentiment is cautious amid bearish technical signals and uncertain revenue sustainability beyond 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
